Thelansis

Fuchs Endothelial Dystrophy (FED) Market Outlook Thelansis’s “Fuchs Endothelial Dystrophy (FED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fuchs Endothelial Dystrophy (FED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest ...

  Fuchs endothelial dystrophy (FED) is a primary, progressive corneal endothelial disorder that causes corneal edema and vision loss. The first signs of FED usually appear between the fifth and seventh decades of life. They are characterized by progressive accumulation of focal excrescences, termed “guttae,” and thickening of Descemet’s membrane, a collagen-rich layer secreted by endothelial cells. Endothelial cell density and functionality as the cornea's "pump" eventually decline, resulting in vision-threatening corneal edema. Although the presence of corneal guttae is not pathognomonic for FED, the development of stromal edema does. Symptoms include visual blurring, most notably in the morning, and stromal and epithelial edema caused by relatively low tear film osmolality. FED has been linked to mutations in collagen VIII, a vital component of the Descemet's membrane secreted by endothelial cells. FED is divided into four stages, beginning with early signs of gutta...